We analyzed medical records data from MSM receiving HIV care at 9 HOPS clinics, including 3 Ryan White Program-funded sites, during January 1, 2011 to December 31, 2019. We included participants with at least 2 HOPS encounters, at least 2 years of observation, and at least 1 CD4+ T-lymphocyte count (CD4) and plasma HIV ribonucleic acid ([RNA] viral load [VL]) test result performed during observation. We excluded participants with injection drug use HIV risk, or those who had a positive HCV antibody or HCV RNA (VL) test before or at the start of observation (baseline date, see definition below). In addition, we censored observation during follow-up for participants after their first positive HCV antibody or HCV VL test. We then evaluated HCV antibody testing during follow-up among MSM without evidence of current or prior HCV infection. We performed a subanalysis for those participants who completed at least 1 ACASI survey during 2011–2019.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.